154 related articles for article (PubMed ID: 9613756)
21. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I
Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112
[TBL] [Abstract][Full Text] [Related]
22. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
Trenkwalder C; Benes H; Grote L; Happe S; Högl B; Mathis J; Saletu-Zyhlarz GM; Kohnen R;
Mov Disord; 2007 Apr; 22(5):696-703. PubMed ID: 17274039
[TBL] [Abstract][Full Text] [Related]
23. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.
Fulda S; Wetter TC
Brain; 2008 Apr; 131(Pt 4):902-17. PubMed ID: 17932100
[TBL] [Abstract][Full Text] [Related]
24. Relationship of periodic leg movements and severity of restless legs syndrome: a study in unmedicated and medicated patients.
Hornyak M; Hundemer HP; Quail D; Riemann D; Voderholzer U; Trenkwalder C
Clin Neurophysiol; 2007 Jul; 118(7):1532-7. PubMed ID: 17531532
[TBL] [Abstract][Full Text] [Related]
25. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
Allen RP; Ondo WG; Ball E; Calloway MO; Manjunath R; Higbie RL; Lee MR; Nisbet PA
Sleep Med; 2011 May; 12(5):431-9. PubMed ID: 21493132
[TBL] [Abstract][Full Text] [Related]
26. Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome.
Benes H
Sleep Med; 2006 Jan; 7(1):31-5. PubMed ID: 16194624
[TBL] [Abstract][Full Text] [Related]
27. Dopa responsive insomnia: a forme fruste or precursor of restless legs syndrome?
Prakash S
J Neurol Sci; 2012 May; 316(1-2):170-2. PubMed ID: 22349357
[TBL] [Abstract][Full Text] [Related]
28. Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome.
Garcia-Borreguero D; Larrosa O; Granizo JJ; de la Llave Y; Hening WA
Sleep; 2004 Jun; 27(4):669-73. PubMed ID: 15283001
[TBL] [Abstract][Full Text] [Related]
29. The treatment of the restless leg syndrome with or without periodic leg movements in sleep.
Montplaisir J; Lapierre O; Warnes H; Pelletier G
Sleep; 1992 Oct; 15(5):391-5. PubMed ID: 1360697
[TBL] [Abstract][Full Text] [Related]
30. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study].
Wetter TC; Trenkwalder C; Stiasny K; Pollmächer T; Kazenwadel J; Kohnen R; Künzel M; Oertel WH
Wien Med Wochenschr; 1995; 145(17-18):525-7. PubMed ID: 8588396
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
33. A randomized controlled study of pergolide in patients with restless legs syndrome.
Wetter TC; Stiasny K; Winkelmann J; Buhlinger A; Brandenburg U; Penzel T; Medori R; Rubin M; Oertel WH; Trenkwalder C
Neurology; 1999 Mar; 52(5):944-50. PubMed ID: 10102410
[TBL] [Abstract][Full Text] [Related]
34. [Six months treatment of restless legs syndrome with levodopa/benserazide in domiciliary practice].
Mühlau G
MMW Fortschr Med; 2004 Dec; 146(Suppl 3-4):87-93. PubMed ID: 15662897
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of the neurological sleep disorders restless legs syndrome and narcolepsy].
Walther BW; Schulz H
Z Arztl Fortbild Qualitatssich; 2001 Jan; 95(1):23-6. PubMed ID: 11233489
[TBL] [Abstract][Full Text] [Related]
36. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial.
Merlino G; Dolso P; Canesin R; Cancelli I; Valente M; Gigli GL
Neuropsychobiology; 2006; 54(3):195-200. PubMed ID: 17314491
[TBL] [Abstract][Full Text] [Related]
37. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.
Trenkwalder C; Hundemer HP; Lledo A; Swieca J; Polo O; Wetter TC; Ferini-Strambi L; de Groen H; Quail D; Brandenburg U;
Neurology; 2004 Apr; 62(8):1391-7. PubMed ID: 15111679
[TBL] [Abstract][Full Text] [Related]
39. Transient restless legs-like syndrome as a complication of opiate withrawal.
Scherbaum N; Stüper B; Bonnet U; Gastpar M
Pharmacopsychiatry; 2003; 36(2):70-2. PubMed ID: 12734764
[TBL] [Abstract][Full Text] [Related]
40. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
